Asciminib single agent

Phase 2

Novartis AG (NVS)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Chronic Myelogenous Leukemia

View Full Landscape

Drug Information

Target Indication

Chronic Myelogenous Leukemia

Clinical Trial

NCT07354074

Last updated: 5/5/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/25/2022

Scemblix

Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (Ph+ CML CP). Scemblix is indicated for the treatment of adult patients with Ph+ CML-CP with the T315I mutation who are resistant to, intolerant to or ineligible for ponatinib (see section 5.1).

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Benazepril plus hydrochlorothiazidePhase 3

Hypertension

Verteporfin PDTPhase 3